Trial Profile
Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study for the Assessment of Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Single and Multiple Ascending Intravenous and Subcutaneous Doses of OSE-127 in Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 02 Mar 2023
Price :
$35
*
At a glance
- Drugs Lusvertikimab (Primary) ; Lusvertikimab (Primary)
- Indications Autoimmune disorders; Sjogren's syndrome; Ulcerative colitis
- Focus Adverse reactions; First in man
- Sponsors OSE Immunotherapeutics
- 22 Feb 2023 According to OSE media release, results from this study will be published online in the peer-reviewed "The Journal of Immunology" of positive phase I clinical results.
- 02 Dec 2019 Status changed from recruiting to completed, according to an OSE Immunotherapeutics media release.
- 02 Dec 2019 Results presented in an OSE Immunotherapeutics media release.